Get the Stockscreener App
5.40
5.88%
0.30
After Hours:
5.48
0.08
+1.48%
Atai Life Sciences N V stock is traded at $5.40, with a volume of 5.21M.
It is up +5.88% in the last 24 hours and up +16.63% over the past month.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.
See More
Previous Close:
$5.10
Open:
$5.21
24h Volume:
5.21M
Relative Volume:
0.90
Market Cap:
$1.16B
Revenue:
$2.59M
Net Income/Loss:
$-137.89M
P/E Ratio:
-6.6667
EPS:
-0.81
Net Cash Flow:
$-69.76M
1W Performance:
-1.28%
1M Performance:
+16.63%
6M Performance:
+318.60%
1Y Performance:
+390.91%
1-Day Range:
$5.06
$5.43
1-Week Range:
$5.06
$5.8299
52-Week Range:
$1.04
$5.965
Atai Life Sciences N V Stock (ATAI) Company Profile
Name
Atai Life Sciences N V
Sector
Industry
Phone
49 89 2153 9035
Address
PROF. J.H. BAVINCKLAAN 7, AMSTELVEEN
Compare ATAI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATAI
Atai Life Sciences N V
|
5.40 | 1.19B | 2.59M | -137.89M | -69.76M | -0.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Atai Life Sciences N V Stock (ATAI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-29-25 | Initiated | Oppenheimer | Outperform |
| Nov-18-24 | Reiterated | H.C. Wainwright | Buy |
| Apr-03-24 | Upgrade | Maxim Group | Hold → Buy |
| Nov-01-22 | Initiated | Loop Capital | Buy |
| Nov-30-21 | Initiated | Maxim Group | Buy |
| Nov-11-21 | Initiated | ROTH Capital | Buy |
| Oct-18-21 | Initiated | H.C. Wainwright | Buy |
| Sep-01-21 | Initiated | Jefferies | Buy |
| Jul-13-21 | Initiated | Berenberg | Buy |
| Jul-13-21 | Initiated | Canaccord Genuity | Buy |
| Jul-13-21 | Initiated | Cantor Fitzgerald | Buy |
| Jul-13-21 | Initiated | Citigroup | Buy |
| Jul-13-21 | Initiated | Cowen | Outperform |
| Jul-13-21 | Initiated | Credit Suisse | Outperform |
| Jul-13-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Jul-08-21 | Initiated | Aegis Capital | Buy |
View All
Atai Life Sciences N V Stock (ATAI) Latest News
Atai Life Sciences Remains Undervalued, Analyst Initiates With Around 125% Stock Upside - Benzinga
How high can Atai Life Sciences N.V. stock goJuly 2025 Recap & Safe Investment Capital Preservation Plans - newser.com
Is now a turning point for Atai Life Sciences N.V.Profit Target & Verified Swing Trading Watchlists - newser.com
Can swing trading help recover from Atai Life Sciences N.V. losses2025 Top Gainers & High Conviction Investment Ideas - newser.com
Needham Initiates ATAI Life Sciences N.V at Buy With $12 Price Target - MarketScreener
Needham Initiates Coverage of Atai Life Sciences N.V. (ATAI) with Buy Recommendation - Nasdaq
How institutional ownership impacts Atai Life Sciences N.V. stockTrade Volume Report & Capital Protection Trade Alerts - newser.com
Ranking Atai Life Sciences N.V. among high performing stocks via tools2025 Valuation Update & Fast Exit/Entry Strategy Plans - newser.com
ATAI Life Sciences files update on Beckley Psytech acquisition plans By Investing.com - Investing.com Nigeria
ATAI Life Sciences files update on Beckley Psytech acquisition plans - Investing.com
ATAI Life Sciences to Acquire Beckley Psytech - TipRanks
ATAI Life Sciences N.V. Announces Acquisition of Beckley Psytech - TradingView
Published on: 2025-10-10 04:54:45 - newser.com
Can technical indicators confirm Atai Life Sciences N.V.’s reversal2025 Growth vs Value & Weekly Market Pulse Updates - newser.com
Atai Life Sciences N.V. stock retracement – recovery analysisWeekly Profit Recap & Verified Trade Idea Suggestions - newser.com
Can trapped investors hope for a rebound in Atai Life Sciences N.V.Portfolio Growth Summary & Low Risk Growth Stock Ideas - newser.com
What to expect from Atai Life Sciences N.V. in the next 30 daysJuly 2025 Selloffs & Technical Confirmation Trade Alerts - newser.com
Evaluating Atai Life Sciences N.V. with trendline analysis2025 Market Overview & Fast Moving Stock Trade Plans - newser.com
What sentiment indicators say about Atai Life Sciences N.V. stockJuly 2025 Volume & Expert Approved Momentum Ideas - newser.com
Will Atai Life Sciences N.V. stock outperform growth indexes2025 Market WrapUp & Safe Capital Growth Tips - newser.com
Quantitative breakdown of Atai Life Sciences N.V. recent moveJuly 2025 Volume & Stepwise Swing Trade Plans - newser.com
How Atai Life Sciences N.V. (9VC) stock responds to job market shifts2025 Price Targets & Expert Curated Trade Setup Alerts - newser.com
How to track smart money flows in Atai Life Sciences N.V.IPO Watch & Weekly Watchlist for Hot Stocks - newser.com
Using RSI to spot recovery in Atai Life Sciences N.V.July 2025 Intraday Action & Expert Verified Movement Alerts - newser.com
Short interest data insights for Atai Life Sciences N.V.2025 Growth vs Value & AI Powered Market Entry Strategies - newser.com
Momentum divergence signals in Atai Life Sciences N.V. chartPortfolio Growth Summary & Risk Managed Investment Signals - newser.com
Why Atai Life Sciences (ATAI) Is in Focus After Positive Depression Data and $239M Shelf Registration Filing - Yahoo Finance
What drives Atai Life Sciences NV stock priceMonthly Performance Summary & High Profit Trading Plans - earlytimes.in
Atai Life Sciences: Still A Decent ProspectBut Only Just (NASDAQ:ATAI) - Seeking Alpha
Atai Life Sciences files to sell 45.32M common shares by selling shareholders - MSN
ATAI Life Sciences files additional details on Beckley Psytech acquisition By Investing.com - Investing.com Australia
ATAI Life Sciences files additional details on Beckley Psytech acquisition - Investing.com India
ATAI Life Sciences to Acquire Beckley Psytech Shares - TipRanks
Atai Life Sciences N V Stock (ATAI) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):